Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22712642 | 0.86 | MAPT (0.38) | MAPTRAB9ASMN1; SMN2POLBTLR8 | |
| SCHEMBL18987205 | 0.81 | MAPT (0.37) | MAPTRAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL31157958 | 0.80 | MPO (0.42) | — | |
| SCHEMBL31157927 | 0.79 | MEN1 (0.46) | MAPTRAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL19011644 | 0.79 | — | — | |
| SCHEMBL1982056 | 0.77 | HSPB1 (0.48) | MAPTRAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL30079808 | 0.77 | HSPB1 (0.48) | MAPTRAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL18987381 | 0.71 | AR (0.34) | — | |
| SCHEMBL23927078 | 0.70 | HSPB1 (0.48) | MAPTRAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL19011614 | 0.70 | MAPT (0.36) | MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390394-B1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-20200377485-A1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377485-A1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | KCNA3, KCNN3, KCND3 | MAPT 3209/4885RAB9A 1408/4885SMN1; SMN2 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.